GLP-1

Pemvidutide (Altimmune): The GLP-1/Glucagon Agonist that Preserves Muscle

Deep dive into Pemvidutide (ALT-801), the dual agonist demonstrating massive fat reduction with unprecedented preservation of lean muscle mass in Phase 2 MOMENTUM trials.

CalcMyPeptide Editorial•9 min read•April 6, 2026

Table of Contents

⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.

The Dual-Agonist Advantage

Pemvidutide (Altimmune) is a GLP-1/Glucagon receptor dual-agonist. While GLP-1 agonism provides appetite suppression and delayed gastric emptying, the glucagon component adds hepatic fat oxidation, increased energy expenditure (thermogenesis), and aggressive mobilization of adipose stores.

This dual mechanism theoretically produces more targeted fat loss while sparing lean tissue. In Phase II data (MOMENTUM trial), approximately 75% of total weight lost was adipose tissue—a dramatically better ratio than GLP-1 monotherapy.

NAFLD and Liver Fat

Glucagon receptors are densely expressed in hepatocytes. Pemvidutide's glucagon agonism drives rapid clearance of hepatic triglycerides, making it a leading candidate for non-alcoholic fatty liver disease (NAFLD/MASH). Liver fat reductions of 50-70% have been observed in early trials.

❓ Frequently Asked Questions

Does Pemvidutide cause less muscle loss than semaglutide?▼

Phase II data suggests significantly better lean mass preservation. Approximately 75% of total weight lost was adipose tissue, meaning only 25% was lean mass—a substantially better ratio than semaglutide (~61% fat / ~39% lean).

When will Pemvidutide be available?▼

Pemvidutide is currently in Phase III clinical trials (as of mid-2026). If endpoints are met, FDA submission and potential approval are projected for 2027-2028. Until then, it is available only as a research peptide.

Semaglutide Dose Calculator: How to Measure Your Weekly Injection

7 min read

Tirzepatide vs Semaglutide: Dosing, Efficacy and Half-Life Compared

10 min read

Retatrutide: The Triple Agonist GLP-1 Peptide — Dosing and PK Guide

11 min read